Last updated on February 2020

Study of Antibody for Methamphetamine Outpatient Therapy

Brief description of study

This study evaluates the ability of IXT-m200 to change methamphetamine concentrations in blood and alter the way methamphetamine feels. Participants will receive either placebo, a low or high dose of IXT-m200, in addition to methamphetamine challenge doses.

Detailed Study Description

IXT-m200 is a monoclonal antibody that binds to methamphetamine in the blood. The main purpose of this study is to look at the effects of IXT-m200 on the pharmacokinetics of methamphetamine and on methamphetamine liking effects. Additionally, the study will determine IXT-m200 pharmacokinetics, safety and tolerability in subjects with methamphetamine use disorder. Qualified subjects will receive a single dose of IXT-m200 followed by up to 4 methamphetamine challenge doses.

Clinical Study Identifier: NCT03336866

Find a site near you

Start Over

PRA Health Sciences

Salt Lake City, UT United States
  Connect »

Anaheim Clinical Trials

Anaheim, CA United States
  Connect »